ReviewTheScientificWorldJournal2013
Alternative splicing for diseases, cancers, drugs, and databases.
Review in TheScientificWorldJournal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 41 citations in OpenAlex.
- Looking beyond the ER, PR, and HER2: what's new in the ARsenal for combating breast cancer?Reproductive biology and endocrinology : RB&E · 2025Review
- RNA Splicing Aberrations in Hereditary Cancer: Insights from Turkish Patients.Current issues in molecular biology · 2024Article
- RNA structure in alternative splicing regulation: from mechanism to therapy.Acta biochimica et biophysica Sinica · 2024Review
- Exon nomenclature and classification of transcripts database (ENACTdb): a resource for analyzing alternative splicing mediated proteome diversity.Bioinformatics advances · 2024Article
- RNA virus infections and their effect on host alternative splicing.Antiviral research · 2023Review
- Androgen receptor and its splice variant, AR-V7, differentially induce mRNA splicing in prostate cancer cells.Scientific reports · 2021Article
- Prognostic Significance of Alternative Splicing Genes in Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma.International journal of general medicine · 2021Article
- MMSET I acts as an oncoprotein and regulates GLO1 expression in t(4;14) multiple myeloma cells.Leukemia · 2019Article
- A novel alternative splicing-based prediction model for uteri corpus endometrial carcinoma.Aging · 2019Article
- A Novel Prognostic Index Based on Alternative Splicing in Papillary Renal Cell Carcinoma.Frontiers in genetics · 2019Article
- Alternative splicing and cancer metastasis: prognostic and therapeutic applications.Clinical & experimental metastasis · 2018Review
- Roles of Smads Family and Alternative Splicing Variants of Smad4 in Different Cancers.Journal of Cancer · 2018Review
- KinMap: a web-based tool for interactive navigation through human kinome data.BMC bioinformatics · 2017Article
- Defective control of pre-messenger RNA splicing in human disease.The Journal of cell biology · 2016Review
- Role of the splicing factor SRSF4 in cisplatin-induced modifications of pre-mRNA splicing and apoptosis.BMC cancer · 2015Article
- Regulation of transcriptional activation function of rat estrogen receptor α (ERα) by novel C-terminal splice inserts.Molecular and cellular endocrinology · 2015Article
- Article
- Differential expression of serum/plasma proteins in various infectious diseases: specific or nonspecific signatures.Proteomics. Clinical applications · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alternative splicing is a major diversification mechanism in the human transcriptome and proteome. Several diseases, including cancers, have been associated with dysregulation of alternative splicing. Thus, correcting alternative splicing may restore normal cell physiology in patients with these diseases. This paper summarizes several alternative splicing-related diseases, including cancers and their target genes. Since new cancer drugs often target spliceosomes, several clinical drugs and natural products or their synthesized derivatives were analyzed to determine their effects on alternative splicing. Other agents known to have modulating effects on alternative splicing during therapeutic treatment of cancer are also discussed. Several commonly used bioinformatics resources are also summarized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.